Fibrogen_US_Primary_logo_RGB_M01.jpg
Pamrevlumab Included in Pancreatic Cancer Action Network’s Adaptive Clinical Trial Platform
June 16, 2021 08:00 ET | FibroGen, Inc
SAN FRANCISCO, June 16, 2021 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) announced activation of an experimental arm in the Pancreatic Cancer Action Network's (PanCAN) Precision PromiseSM...
Fibrogen_US_Primary_logo_RGB_M01.jpg
FibroGen Announces First Patient Dosed in ZEPHYRUS, a Phase 3 Clinical Trial of Pamrevlumab for the Treatment of Patients with Idiopathic Pulmonary Fibrosis
July 22, 2019 07:00 ET | FibroGen, Inc
SAN FRANCISCO, July 22, 2019 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN), today announced dosing of the first patient in the ZEPHYRUS Phase 3 clinical study of pamrevlumab in patients with...
Fibrogen_US_Primary_logo_RGB_M01.jpg
FibroGen Reports Third Quarter 2018 Financial Results
November 08, 2018 16:02 ET | FibroGen, Inc
—Roxadustat New Drug Applications under Review in China and Japan——Phase 3 Clinical Trials in IPF and Pancreatic Cancer to Initiate in First Quarter 2019——Conference Call Today at 5:00 p.m. Eastern...
Fibrogen_US_Primary_logo_RGB_M01.jpg
FibroGen Reports Second Quarter 2018 Financial Results
August 07, 2018 16:02 ET | FibroGen, Inc
Roxadustat U.S. Phase 3 Topline Clinical Data Readout on Track for Fourth Quarter of 2018 Feedback from FDA on Pamrevlumab Pivotal Programs in IPF and in Locally Advanced Unresectable Pancreatic...
FibroGen Presents Latest Data From PRAISE Phase 2b Study of Pamrevlumab in Idiopathic Pulmonary Fibrosis at American Thoracic Society 2018
May 21, 2018 16:00 ET | FibroGen, Inc
SAN DIEGO, May 21, 2018 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN), a biopharmaceutical company, today announced that updated results from the company’s randomized, double-blind,...
Fibrogen_US_Primary_logo_RGB_M01.jpg
FibroGen Granted Orphan Drug Designation for Pamrevlumab in the Treatment of Pancreatic Cancer
June 21, 2017 22:09 ET | FibroGen, Inc.
SAN FRANCISCO, June 21, 2017 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN), a science-based biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has granted...
Fibrogen_US_Primary_logo_RGB_M01.jpg
FibroGen Announces Publication of Pamrevlumab (FG-3019) Clinical Data in Pancreatic Cancer Showing Safety and Improved Survival Outcomes in Combination with Chemotherapy
February 03, 2017 11:06 ET | FibroGen, Inc.
SAN FRANCISCO, Feb. 03, 2017 (GLOBE NEWSWIRE) -- FibroGen, Inc., (NASDAQ:FGEN), a science-based biopharmaceutical company, today announced that clinical results from the company’s open-label,...
Fibrogen_US_Primary_logo_RGB_M01.jpg
Pamrevlumab Pancreatic Cancer Clinical Data Presented at ASCO 2017 Gastrointestinal Cancers Symposium
January 20, 2017 17:05 ET | FibroGen, Inc.
SAN FRANCISCO, Jan. 20, 2017 (GLOBE NEWSWIRE) -- FibroGen, Inc. (Nasdaq:FGEN) today announced that updated results from an ongoing clinical study of pamrevlumab (FG-3019) in combination with...
Fibrogen_US_Primary_logo_RGB_M01.jpg
FibroGen Reports Financial Results for the Second Quarter of 2016
August 08, 2016 16:02 ET | FibroGen, Inc.
Enrollment Completed in Placebo-Controlled Study of FG-3019 (Pamrevlumab) in IPF China Phase 3 Top Line Data Expected by Year-End 2016 –Webcast Conference Call Scheduled for 4:30pm EDT Today– ...
Fibrogen_US_Primary_logo_RGB_M01.jpg
FibroGen to Report Second Quarter 2016 Financial Results on August 8, 2016
August 02, 2016 20:00 ET | FibroGen, Inc.
SAN FRANCISCO, Aug. 02, 2016 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN), a research-based biopharmaceutical company focused on the discovery, development, and commercialization of novel...